# OnCo record thyroid (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/thyroid/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "thyroid" ;
  schema:name "Thyroid cancer"@en ;
  schema:description "Thyroid cancer is usually curable with surgery and radioactive iodine, the original theranostic. Rare aggressive forms respond to RET and BRAF inhibitors."@en ;
  schema:url <https://onco.cc/cancers/thyroid/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Thyroid_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q826522> ;
  schema:citation <https://en.wikipedia.org/wiki/Thyroid_cancer> ;
  onco:tag "endocrine", "spike" ;
  onco:related <https://onco.cc/roadmaps/radiopharma-roadmap/>, <https://onco.cc/pairings/braf-mek-neoadjuvant-atc/>, <https://onco.cc/pairings/redifferentiation-rai/>, <https://onco.cc/terms/theranostics/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/technologies/radioiodine-therapy/>, <https://onco.cc/technologies/thyroid-fna-molecular/>, <https://onco.cc/technologies/active-surveillance-thyroid/>, <https://onco.cc/technologies/germline-testing/> ;
  onco:targets <https://onco.cc/targets/ret/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/radioactive-iodine/>, <https://onco.cc/drugs/vandetanib/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/afirma/>, <https://onco.cc/drugs/thyrotropin-alfa/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/sanofi/>, <https://onco.cc/companies/veracyte/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:institutions <https://onco.cc/institutions/gustave-roussy/>, <https://onco.cc/institutions/cruk/>, <https://onco.cc/institutions/md-anderson/>, <https://onco.cc/institutions/mskcc/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/thyroid-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/rai-refractory/>, <https://onco.cc/terms/low-risk-dtc/>, <https://onco.cc/terms/bethesda-category/>, <https://onco.cc/terms/tsh-suppression/>, <https://onco.cc/terms/tert-promoter/>, <https://onco.cc/terms/theranostics/> ;
  onco:trials <https://onco.cc/trials/nct06860971/>, <https://onco.cc/trials/nct04940052/>, <https://onco.cc/trials/nct03690388/>, <https://onco.cc/trials/select-lenvatinib/>, <https://onco.cc/trials/decision-sorafenib/>, <https://onco.cc/trials/libretto-531/>, <https://onco.cc/trials/arrow-thyroid/>, <https://onco.cc/trials/estimabl2/>, <https://onco.cc/trials/ion-trial/>, <https://onco.cc/trials/hilo/>, <https://onco.cc/trials/roar-atc/>, <https://onco.cc/trials/astra/> ;
  onco:journals <https://onco.cc/journals/endocrine-related-cancer/>, <https://onco.cc/journals/european-thyroid-journal/> ;
  onco:pipeline <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/al2846/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/ideas/idea-atc-triplet-io/>, <https://onco.cc/pairings/braf-mek-neoadjuvant-atc/>, <https://onco.cc/pairings/redifferentiation-rai/>, <https://onco.cc/ideas/idea-thyroid-overdiagnosis-reversal/>, <https://onco.cc/technologies/thyroid-fna-molecular/>, <https://onco.cc/technologies/active-surveillance-thyroid/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/cthpv-dna/>, <https://onco.cc/technologies/targeted-alpha-therapy/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/dermoscopy-ai/> ;
  onco:standardOfCare <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/technologies/thyroid-fna-molecular/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/terms/bethesda-category/>, <https://onco.cc/technologies/active-surveillance-thyroid/>, <https://onco.cc/ideas/idea-thyroid-overdiagnosis-reversal/>, <https://onco.cc/trials/estimabl2/>, <https://onco.cc/trials/ion-trial/>, <https://onco.cc/terms/low-risk-dtc/>, <https://onco.cc/terms/tsh-suppression/>, <https://onco.cc/drugs/radioactive-iodine/>, <https://onco.cc/technologies/radioiodine-therapy/>, <https://onco.cc/trials/hilo/>, <https://onco.cc/trials/select-lenvatinib/>, <https://onco.cc/trials/decision-sorafenib/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/pairings/redifferentiation-rai/>, <https://onco.cc/terms/rai-refractory/>, <https://onco.cc/targets/ret/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/trials/libretto-531/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/vandetanib/>, <https://onco.cc/trials/roar-atc/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/pairings/braf-mek-neoadjuvant-atc/>, <https://onco.cc/ideas/idea-atc-triplet-io/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/terms/tsh-suppression/>, <https://onco.cc/fronts/supportive-care/> .